IONS: Ionis Pharmaceuticals Inc. Stocks News on April 2, 2025

IONS

MT Newswires

2 days ago

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target

Ionis to present at upcoming investor conferences

IONS

Business Wire

2 days ago

Ionis to present at upcoming investor conferences

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

IONS

Zacks

5 days ago

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Ionis and Sobi agree on olezarsen commercialisation

IONS

Pharmaceutical Technology

6 days ago

Ionis and Sobi agree on olezarsen commercialisation

IONS

Zacks

6 days ago

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

IONS

MT Newswires

7 days ago

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

IONS

Business Wire

7 days ago

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

IONS

Insider Monkey

7 days ago

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts

IONS

Zacks

12 days ago

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

IONS

Pharmaceutical Technology

21 days ago

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

IONS

Benzinga

21 days ago

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono

IONS

Zacks

21 days ago

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono

Ono pays $280M to license Ionis rare disease drug

IONS

BioPharma Dive

21 days ago

Ono pays $280M to license Ionis rare disease drug

IONS

MT Newswires

21 days ago

Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

IONS

Business Wire

21 days ago

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

IONS

Zacks

22 days ago

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

IONS

MT Newswires

23 days ago

Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

IONS

Business Wire

23 days ago

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...

IONS

GuruFocus.com

a month ago

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...

IONS

Business Wire

a month ago

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James

IONS

TipRanks

a month ago

Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James

IONS

Insider Monkey

a month ago

Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus

IONS

Zacks

a month ago

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus

IONS

Morningstar Research

a month ago

Analyst Report: Ionis Pharmaceuticals, Inc.

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

IONS

Business Wire

a month ago

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

IONS

Simply Wall St.

a month ago

Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

IONS

Thomson Reuters StreetEvents

a month ago

Q4 2024 Ionis Pharmaceuticals Inc Earnings Call

IONS

GuruFocus.com

a month ago

Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

IONS

Benzinga

a month ago

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

IONS

Zacks

a month ago

Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say

IONS

Zacks

a month ago

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

IONS

MT Newswires

a month ago

Ionis Pharmaceuticals Q4 Net Loss Widens, Revenue Falls; 2025 Sales Guidance Set

IONS

Associated Press Finance

a month ago

Ionis Pharmaceuticals: Q4 Earnings Snapshot

Ionis reports fourth quarter and full year 2024 financial results

IONS

Business Wire

a month ago

Ionis reports fourth quarter and full year 2024 financial results

IONS

Insider Monkey

a month ago

Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January

IONS

Zacks

a month ago

Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

IONS

Zacks

2 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

IONS

Insider Monkey

2 months ago

Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently

IONS

Insider Monkey

2 months ago

Why Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to Analysts

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,229,463, According to a Recent SEC Filing

Ionis to hold fourth quarter and full year 2024 financial results webcast

IONS

Business Wire

2 months ago

Ionis to hold fourth quarter and full year 2024 financial results webcast

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed

IONS

GlobeNewswire

2 months ago

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

IONS

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 01/21/2025

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,091,444, According to a Recent SEC Filing

IONS

Insider Monkey

3 months ago

Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

IONS

PR Newswire

3 months ago

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

IONS

Zacks

3 months ago

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

IONS

PR Newswire

3 months ago

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

IONS

Simply Wall St.

3 months ago

Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?

IONS

Morningstar Research

3 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

IONS

Morningstar Research

3 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

FDA approves Ionis’ TRYNGOLZA for FCS treatment

IONS

Pharmaceutical Technology

3 months ago

FDA approves Ionis’ TRYNGOLZA for FCS treatment

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza

IONS

Zacks

3 months ago

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

IONS

Benzinga

3 months ago

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

Ionis gets a milestone approval; Another top FDA official to step down

IONS

BioPharma Dive

3 months ago

Ionis gets a milestone approval; Another top FDA official to step down

IONS

MT Newswires

3 months ago

Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

IONS

PR Newswire

3 months ago

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

IONS

Zacks

4 months ago

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

IONS

Zacks

4 months ago

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%

IONS

Morningstar Research

4 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

IONS

Zacks

4 months ago

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Theratechnologies enters exclusive licensing agreement with Ionis

IONS

TipRanks

4 months ago

Theratechnologies enters exclusive licensing agreement with Ionis

IONS

MT Newswires

4 months ago

Theratechnologies to Commercialize Two RNA-targeted Medicines in Canada

IONS

MT Newswires

4 months ago

Theratechnologies Acquires Canadian Rights to 2 RNA Medicines From Ionis Pharmaceuticals

IONS

Zacks

4 months ago

Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?

IONS

Insider Monkey

4 months ago

Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?

IONS

Insider Monkey

4 months ago

Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now

IONS

Zacks

4 months ago

Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks

IONS

Simply Wall St.

5 months ago

Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus

IONS

Zacks

5 months ago

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus

IONS

Zacks

5 months ago

Company News for Nov 7, 2024

IONS

PR Newswire

5 months ago

Ionis to present at upcoming investor conferences

Ionis announces design for Phase III trial of Angelman syndrome therapy

IONS

Clinical Trials Arena

5 months ago

Ionis announces design for Phase III trial of Angelman syndrome therapy

IONS

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Ionis Pharmaceuticals Inc Earnings Call

IONS

GuruFocus.com

5 months ago

Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...

IONS

MT Newswires

5 months ago

Ionis Reports Late-Stage Trial Design in Angelman Syndrome

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

IONS

Motley Fool

5 months ago

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

IONS

Zacks

5 months ago

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

IONS

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

IONS

MT Newswires

5 months ago

Ionis Pharmaceuticals' Q3 Loss Narrows, Revenue Decreases

IONS

Associated Press Finance

5 months ago

Ionis Pharmaceuticals: Q3 Earnings Snapshot

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

IONS

PR Newswire

5 months ago

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis reports third quarter 2024 financial results

IONS

PR Newswire

5 months ago

Ionis reports third quarter 2024 financial results

IONS

MT Newswires

5 months ago

Ionis Pharmaceuticals Gets FDA Acceptance of New Drug Application for Angioedema Treatment

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

IONS

PR Newswire

5 months ago

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

IONS

Zacks

5 months ago

Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

IONS

Zacks

5 months ago

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

IONS

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IONS

Simply Wall St.

5 months ago

Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years

Ionis to hold third quarter 2024 financial results webcast

IONS

PR Newswire

5 months ago

Ionis to hold third quarter 2024 financial results webcast

EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN

IONS

Pharmaceutical Technology

5 months ago

EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN

IONS

MT Newswires

5 months ago

Ionis Pharmaceuticals Says Wainzua Recommended for Approval in European Union

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

IONS

PR Newswire

5 months ago

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

IONS

Insider Monkey

6 months ago

Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

IONS

GlobeNewswire

6 months ago

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

IONS

PR Newswire

6 months ago

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

IONS

Zacks

6 months ago

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

IONS

Morningstar Research

6 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

IONS

MT Newswires

6 months ago

Latest Ionis Pharmaceuticals Inc. (IONS) News on April 2, 2025

Share on Social Networks: